Outlook 2011 - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

Outlook 2011
Industry executives share insight into the future direction of drug manufacturing and the supply chain. This article contains online bonus material.


Pharmaceutical Technology
Volume 35, Issue 1

Manufacturing performance

PharmTech: We often hear the phrase "operational excellence" as a goal for a company's manufacturing activities. How do you define operational excellence?

Maddaluna (Pfizer): Operational excellence is all about optimizing output while reducing input—streamlining our internal and external processes (across laboratory, packaging, manufacturing, and all other areas) to deliver a quality and compliant product. OEE (i.e., operational excellence plus effectiveness) is our measure of success.

Bailey (PwC): This may not sound particularly insightful, but it's powerful. Operational excellence can be defined as achieving the key quantitative and qualitative metrics that are required by a supply-chain organization's three key stakeholders: meeting the needs of the business for assurance of supply and competitive total delivered cost; meeting the needs of regulators for assured quality and effective risk management; and meeting the needs of society for responsible corporate citizenship (e.g., as it relates to environmental issues). This framework may look different in practice based on any particular company's particular situation, but it can be the starting point for a powerful and integrated cascade of performance metrics.

Villax (Hovione): The industry as a whole is still looking for what it means; we are a good 20 years away from the Toyota way. For our industry to start comprehending what operational excellence is, it needs to cease being in denial and defending its poor record by blaming FDA and regulatory handcuffs. Our industry is at Sigma Two or Three. Operational excellence is a matter of measuring to allow managing. It is a matter of developing a problem-solving mindset, so that deviations are truly tackled and root causes are confronted and fixed before the next batch. It is a matter of adopting methodologies and using them well and systematically. A good indicator of how well are we doing in terms of operational excellence is measuring how many of our people know and use things such as 8D [a problem-solving methodology for product and process improvement], failure modes and effects analysis (FMEA), 5S [a workplace organization methodology], single-minute exchange of die (SMED), overall equipment effectiveness (OEE), and statistical process control (SPC). However before you have operational excellence, you need to have a genuine quality culture in the company across all areas and up and down the hierarchy; this is rare. At the start, you need quality which Henry Ford said was "doing it right when no one is looking."

Hamby (Ash Stevens): Operational excellence at all levels is central to the success of a quality contract pharmaceutical manufacturing company. CMOs generally possess a track record for consistently delivering quality APIs on schedule and on budget as well as possessing an excellent regulatory inspection history and strong environmental, health, and safety program. Quality encompasses a number of tangible and intangible attributes. In general, quality refers to the ability to deliver API that meets all specifications and is compliant with all regulations. In reality, quality goes beyond this definition. Quality CMOs share the same goals as their sponsor clients and are equally committed to the goals of the project as the sponsor. Communication and relationship building are more difficult to assess, but nonetheless, are important. A quality CMO fosters communicative and active relationships, timely communicates problems or delays, and rapidly adjusts to and resolves technical issues.

External manufacturing

PharmTech: From an industry view, how do you think contract or external manufacturing

has evolved in a pharmaceutical company's manufacturing strategy?

Maddaluna (Pfizer): The "make what you sell; sell what you make" model is a thing of the past—the industry has adopted a globally competitive cost manufacturing model that incorporates contract manufacturing as a strategic business tool. Pfizer's ability to extend the manufacturing network to encompass an external-supplier network provides access to a broad range of suppliers and technologies that facilitate the success of its business units. For Pfizer, key factors for keeping manufacturing in-house include the need to:

  • Codevelop and launch new products jointly with research
  • Improve processes and extract value throughout the product's life cycle
  • Ensure quality/compliance
  • Perform difficult processes, implement unique technologies, and support business goals with greater efficiency and effectiveness than third parties
  • Operate in a given country due to commercial requirements.

Bailey (PwC): It's obvious that contract manufacturing is playing an increasingly important role in the manufacturing strategies of pharmaceutical and biotech companies. There are many reasons for this, including the emergence of a growing and highly capable contract manufacturing market, and pharma's interest in turning fixed costs into variable costs. Increasingly, the question being posed by top corporate management—CEOs, CFOs and other assorted Os—is why they should be making anything in-house. In response, leading supply organizations have redefined their mission and mindset around supply management rather than manufacturing. Companies that do a good job around contract manufacturing do five things particularly well:

First, they link the contract-manufacturing strategies to their broader business strategies and manufacturing-network strategies. Second, they have a well-defined and commonly understood operating

model that defaults to a "center-led" approach for managing most contract manufacturing relationships. Third, they have standardized enablers (processes, key performance indicators, scorecards, and relationship-management frameworks). Fourth, they use the full array of tools at their disposal to manage the economics of contract-manufacturing relationships. Fifth, they have robust and effective risk-management plans in place, supported by an anticipatory analytic environment rather than a reactive firefighting environment.

Villax (Hovione): Outsourcing ceases to be just a buzzword, an opportunistic option or a tactical decision when Big Pharma starts measuring cost properly. When shareholders press for performance and finance has run out of options, it starts addressing cost, and given the uncertainty of the pipelines and the high costs of execution, it is clear that Big Pharma makes a far better deal when it ceases to develop and manufacture in-house. Doing otherwise represents a very high capital expense cost and a very high operating cost because Big Pharma will inevitably operate to very low occupancy rates. Time has come for finance to cause Big Pharma organizations to take these tough decisions. By 2020, Big Pharma won't have vessels bigger than 20 L, except if tax savings remain available at certain key locations.

Hamby (Ash Stevens): The outsourcing of drug-substance development and manufacturing continues to grow. Large pharmaceutical companies have a number of manufacturing options available to them. Many large companies are building or have manufacturing facilitates in countries where labor cost are less expensive than Western countries such as in Asia. This allows them to take advantage of the labor arbitrage while controlling quality. Most Big Pharma companies have in-house manufacturing capabilities and facilities as well.

Big Pharma has varying philosophies and strategies regarding which projects and intermediates are outsourced to contract manufacturers. Some prefer to outsource lower priority projects to relieve pipeline congestion and increase development capacity or outsource projects with challenging chemistry. Big Pharma is becoming more comfortable with outsourcing manufacturing services and working with outside manufacturing vendors. Some companies such as Eli Lilly are moving to a completely outsourced manufacturing model. Other successful large pharmaceutical companies will likely follow suit. Large pharma and many larger biotechs typically maintain a list of preferred manufacturing vendors they have previously vetted for work. A contract manufacturer may be assigned challenging or lower priority projects initially to assess its abilities before being fully vetted to work on important CGMP manufacturing projects. Large pharmaceutical companies maintain metrics on vendors as a way to measure and track their performance.


ADVERTISEMENT

blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
FDASIA was signed into law two years ago. Where has the most progress been made in implementation?
Reducing drug shortages
Breakthrough designations
Protecting the supply chain
Expedited reviews of drug submissions
More stakeholder involvement
Reducing drug shortages
31%
Breakthrough designations
8%
Protecting the supply chain
42%
Expedited reviews of drug submissions
8%
More stakeholder involvement
12%
View Results
Jim Miller Outsourcing Outlook Jim Miller Health Systems Raise the Bar on Reimbursing New Drugs
Cynthia Challener, PhD Ingredients Insider Cynthia ChallenerThe Mainstreaming of Continuous Flow API Synthesis
Jill Wechsler Regulatory Watch Jill Wechsler Industry Seeks Clearer Standards for Track and Trace
Siegfried Schmitt Ask the Expert Siegfried SchmittData Integrity
Sandoz Wins Biosimilar Filing Race
NIH Translational Research Partnership Yields Promising Therapy
Clusters set to benefit from improved funding climate but IP rights are even more critical
Supplier Audit Program Marks Progress
FDA, Drug Companies Struggle with Compassionate Use Requests
Source: Pharmaceutical Technology,
Click here